These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22050597)

  • 21. Regulated genes in psoriatic skin during treatment with fumaric acid esters.
    Onderdijk AJ; Balak DM; Baerveldt EM; Florencia EF; Kant M; Laman JD; van IJcken WF; Racz E; de Ridder D; Thio HB; Prens EP
    Br J Dermatol; 2014 Oct; 171(4):732-41. PubMed ID: 24852654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Long-term safety and efficacy of etanercept in the treatment of psoriasis].
    Zaragoza V; Pérez A; Sánchez JL; Oliver V; Martínez L; Alegre V
    Actas Dermosifiliogr; 2010; 101(1):47-53. PubMed ID: 20109392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept.
    Kanelleas A; Liapi C; Katoulis A; Stavropoulos P; Avgerinou G; Georgala S; Economopoulos T; Stavrianeas NG; Katsambas A
    Clin Exp Dermatol; 2011 Dec; 36(8):845-50. PubMed ID: 21790728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Our experience with etanercept in the treatment of psoriasis.
    Kokelj F; Miertusova Tothova S; Patamia M; Trevisan G
    Acta Dermatovenerol Croat; 2006; 14(4):241-5. PubMed ID: 17311738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients.
    Malaviya R; Sun Y; Tan JK; Wang A; Magliocco M; Yao M; Krueger JG; Gottlieb AB
    J Am Acad Dermatol; 2006 Oct; 55(4):590-7. PubMed ID: 17010737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.
    Gisondi P; Del Giglio M; Cotena C; Girolomoni G
    Br J Dermatol; 2008 Jun; 158(6):1345-9. PubMed ID: 18410408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of erythrodermic psoriasis with etanercept.
    Esposito M; Mazzotta A; de Felice C; Papoutsaki M; Chimenti S
    Br J Dermatol; 2006 Jul; 155(1):156-9. PubMed ID: 16792768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of etanercept on urine neopterin levels in patients with psoriasis in a controlled, open-label study.
    Koc E; Tunca M; Akgul EO; Akar A; Kurt Y; Kurumlu Z; Erbil K; Kilic S
    J Dermatol; 2009 Apr; 36(4):191-6. PubMed ID: 19348656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of the fully human monoclonal antibody MOR102 (#5) against intercellular adhesion molecule 1 in the psoriasis-severe combined immunodeficient mouse model.
    Boehncke WH; Ochsendorf FR; Noll S; Urban M; Popp A; Waldherr D; Haunschild J; Litzenburger T
    Br J Dermatol; 2005 Oct; 153(4):758-66. PubMed ID: 16181457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Analysis of lymphocyte populations in psoriatic plaques following inhibition of tumor necrosis factor alpha with etanercept].
    Mahiques L; Pitarch G; Sánchez-Carazo JL; Pérez-Ferriols A; Soriano CJ; Alegre V
    Actas Dermosifiliogr; 2007 Oct; 98(8):539-44. PubMed ID: 17919428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
    Bansback NJ; Ara R; Barkham N; Brennan A; Fraser AD; Conway P; Reynolds A; Emery P
    Rheumatology (Oxford); 2006 Aug; 45(8):1029-38. PubMed ID: 16782734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of calcipotriol on etanercept partial responder psoriasis vulgaris and psoriatic arthritis patients.
    Campione E; Mazzotta A; Paternò EJ; Diluvio L; Prinz JC; Chimenti S
    Acta Derm Venereol; 2009; 89(3):288-91. PubMed ID: 19479128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
    Gordon K; Korman N; Frankel E; Wang H; Jahreis A; Zitnik R; Chang T
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S101-11. PubMed ID: 16488320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis.
    Elewski B; Leonardi C; Gottlieb AB; Strober BE; Simiens MA; Dunn M; Jahreis A
    Br J Dermatol; 2007 Jan; 156(1):138-42. PubMed ID: 17199580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-CD11a ameliorates disease in the human psoriatic skin-SCID mouse transplant model: comparison of antibody to CD11a with Cyclosporin A and clobetasol propionate.
    Zeigler M; Chi Y; Tumas DB; Bodary S; Tang H; Varani J
    Lab Invest; 2001 Sep; 81(9):1253-61. PubMed ID: 11555673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IL-1RL2 and its ligands contribute to the cytokine network in psoriasis.
    Blumberg H; Dinh H; Dean C; Trueblood ES; Bailey K; Shows D; Bhagavathula N; Aslam MN; Varani J; Towne JE; Sims JE
    J Immunol; 2010 Oct; 185(7):4354-62. PubMed ID: 20833839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept.
    Wolf P; Hofer A; Legat FJ; Bretterklieber A; Weger W; Salmhofer W; Kerl H
    Br J Dermatol; 2009 Jan; 160(1):186-9. PubMed ID: 19067710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical experience with etanercept in the treatment of psoriasis].
    Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
    Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model.
    Villadsen LS; Schuurman J; Beurskens F; Dam TN; Dagnaes-Hansen F; Skov L; Rygaard J; Voorhorst-Ogink MM; Gerritsen AF; van Dijk MA; Parren PW; Baadsgaard O; van de Winkel JG
    J Clin Invest; 2003 Nov; 112(10):1571-80. PubMed ID: 14617758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Psoriasis SCID-mouse model].
    Pfeffer J; Kaufmann R; Boehncke WH
    Hautarzt; 2006 Jul; 57(7):603-9. PubMed ID: 16028077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.